CD34 and neoplasm: To investigate tumor cell-intrinsic factors that determine anti-PD1 responsiveness, we performed a pooled loss-of-function genetic screen using humanized mice in which human immune cells were recapitulated via engraftment of CD34+ hematopoietic stem cells [13] (Fig. 1a).